In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid

B. Hellmark, M. Unemo, Å. Nilsson-Augustinsson, B. Söderquist

► To cite this version:

B. Hellmark, M. Unemo, Å. Nilsson-Augustinsson, B. Söderquist. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. *European Journal of Clinical Microbiology and Infectious Diseases*, 2010, 29 (5), pp.591-595. 10.1007/s10096-010-0902-6 . hal-00576102

HAL Id: hal-00576102

<https://hal.science/hal-00576102>

Submitted on 12 Mar 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid

B. Hellmark · M. Unemo · Å. Nilsdotter-Augustinsson ·
B. Söderquist

Received: 30 September 2009 / Accepted: 20 February 2010 / Published online: 12 March 2010
© Springer-Verlag 2010

Abstract In recent years, coagulase-negative staphylococci (CoNS) have been increasingly recognised as causative agents of various infections, especially in immunocompromised patients and related to implanted foreign body materials. CoNS, and especially *Staphylococcus epidermidis*, transform into a stationary growth phase and produce biofilm when involved in a foreign body infection, making them difficult to eradicate with antimicrobials. Rifampicin has the ability to penetrate biofilm, but resistance may develop rapidly. To reduce the emergence of resistance, rifampicin should be combined with additional antimicrobials, of which several different ones have been proposed, including the relatively new class of antimicrobials, oxazolidinones, represented by linezolid. Thirty-seven CoNS isolates from patients with prosthetic joint infection were investigated by synergy testing using Etest. Nine antimicrobial combinations, based on either rifampicin or linezolid, were tested. For 16 (43%) of the isolates, a synergistic ($n=5$), additive ($n=14$) and/or antagonistic ($n=11$) effect were identified. In conclusion, Etest is an objective and easily performed in vitro method for antimicrobial synergy testing. However, each isolate requires testing for the specific combination considered for treatment.

Introduction

Prosthetic joint infections (PJIs) are uncommon complications of prosthetic device surgery procedures, but represent harmful conditions with high morbidity and substantial costs. Coagulase-negative staphylococci (CoNS), and especially *Staphylococcus epidermidis*, is the most important pathogen involved in delayed or late onset PJIs [1]. There are no standards for the antimicrobial treatment of PJIs [2] and, during the recent decades, the treatment consisted predominately of cell wall antimicrobials such as isoxazolyl penicillin or glycopeptides [3]. However, without prosthetic joint exchange surgery, the long-term outcome has been disappointing, with a high rate of failures following finite treatment regimens [4–6]. *S. epidermidis* involved in a foreign body infection transforms into a stationary growth phase and produces biofilm. Therefore, cell wall antimicrobials may not be effective, since they do not efficiently penetrate the biofilm and have only a modest effect on bacteria in a non-growing phase [7]. Accordingly, additional antimicrobial agents and/or combinations of antimicrobials for the treatment of foreign body infections have been assessed. Predominantly antimicrobial combinations including rifampicin, which penetrates the biofilm and is effective also against stationary phase bacteria, have been investigated in experimental studies [8–10] as well as in clinical trials [6, 11, 12]. Resistance to rifampicin may rapidly emerge and, therefore, monotherapy should be avoided. To reduce the emergence of resistance to rifampicin, it is, accordingly, recommended to combine it with additional antimicrobials and several antimicrobials have been proposed, including fluoroquinolones [6], linezolid [13] and clindamycin [12]. In addition, linezolid may be a treatment option for multidrug-resistant (MDR) *S. epidermidis*, as monotherapy [13] or in combination with

B. Hellmark (✉) · M. Unemo · B. Söderquist
Department of Laboratory Medicine, Clinical Microbiology,
Örebro University Hospital,
701 85 Örebro, Sweden
e-mail: bengt.hellmark@orebroll.se

Å. Nilsdotter-Augustinsson
Division of Infectious Diseases,
Department of Clinical and Experimental Medicine,
Faculty of Health Sciences, University of Linköping,
Linköping, Sweden

B. Söderquist
Department of Infectious Diseases, Örebro University Hospital,
Örebro, Sweden

rifampicin [14]. However, concerns have been raised due to supposed in vitro antagonism between rifampicin and other antimicrobial agents [3]. This strengthens the need for synergy testing of antimicrobial combinations including rifampicin that are considered for treatment, which may also be needed for all antimicrobial combinations.

The aim of this study was to investigate antimicrobial combinations against *S. epidermidis* that may be of clinical interest for the long-term treatment of PJIs, focusing on

rifampicin and linezolid. In vitro synergy testing was performed using Etest.

Materials and methods

Thirty-seven clinical CoNS isolates obtained during revision surgery for PJIs with extraction or exchange of the prosthetic devices were analysed. Multiple tissue biopsy

Table 1 Minimum inhibitory concentrations (MICs; µg/ml), using Etest, of six antimicrobials in coagulase-negative staphylococcal isolates (n=37) from prosthetic joint infections

	Rifampicin	Linezolid	Ciprofloxacin	Fusidic acid	Clindamycin	Trimethoprim-sulfamethoxazole
<i>S. epidermidis</i>	>32	0.19	8	0.047	0.094	>640
<i>S. epidermidis</i>	>32	0.047	>32	6	>256	>640
<i>S. epidermidis</i>	0.002	0.19	16	12	>256	>640
<i>S. epidermidis</i>	>32	0.19	>32	6	0.023	>640
<i>S. epidermidis</i>	>32	0.19	>32	0.047	>256	>640
<i>S. epidermidis</i>	<0.002	0.125	>32	6	0.047	>640
<i>S. epidermidis</i>	>32	0.19	>32	12	>256	>640
<i>S. epidermidis</i>	0.25	0.125	>32	12	>256	>640
<i>S. epidermidis</i>	0.003	0.19	>32	16	>256	>640
<i>S. epidermidis</i>	>32	0.19	>32	0.047	>256	>640
<i>S. epidermidis</i>	0.003	0.19	>32	0.032	>256	2.5
<i>S. epidermidis</i>	0.003	0.25	>32	12	0.064	>640
<i>S. epidermidis</i>	>32	0.25	>32	0.047	>256	>640
<i>S. epidermidis</i>	6	0.125	3	0.032	>256	>640
<i>S. epidermidis</i>	0.003	0.19	>32	0.032	>256	>640
<i>S. epidermidis</i>	0.003	0.25	>32	0.023	>256	320
<i>S. epidermidis</i>	>32	0.125	>32	6	>256	>640
<i>S. epidermidis</i>	>32	0.25	>32	0.047	>256	>640
<i>S. epidermidis</i>	0.003	0.25	>32	0.032	>256	>640
<i>S. epidermidis</i>	0.002	0.25	>32	6	>256	>640
<i>S. epidermidis</i>	>32	0.19	0.19	0.023	>256	>640
<i>S. epidermidis</i>	>32	0.19	6	0.023	>256	>640
<i>S. epidermidis</i>	>32	0.19	0.047	0.047	>256	>640
<i>S. epidermidis</i>	0.002	0.38	16	6	0.094	480
<i>S. epidermidis</i>	0.003	0.25	0.19	0.047	0.125	5
<i>S. epidermidis</i>	0.003	0.38	16	0.064	0.064	>640
<i>S. epidermidis</i>	0.003	0.25	>32	4	>256	>640
<i>S. epidermidis</i>	0.003	0.25	0.19	0.047	0.094	0.64
<i>S. epidermidis</i>	0.003	0.25	>32	0.016	0.064	480
<i>S. epidermidis</i>	0.003	0.19	>32	8	0.094	>640
<i>S. epidermidis</i>	0.003	0.25	0.25	0.125	>256	0.94
<i>S. epidermidis</i>	0.004	0.19	0.19	0.032	>256	3.8
<i>S. epidermidis</i>	0.003	0.38	0.38	0.032	0.125	0.94
<i>S. capitis</i>	0.012	0.38	0.125	0.064	0.19	1.88
<i>S. haemolyticus</i>	0.006	0.38	>32	12	>256	240
<i>S. simulans</i>	0.006	0.5	4	0.047	0.19	15
<i>S. lugdunensis</i>	<0.002	0.094	0.25	0.047	0.064	1.88

samples, usually five or more, were taken perioperatively. The isolates were collected from patients with infected hip ($n=27$), knee ($n=9$) and elbow joint ($n=1$) prostheses. The isolates comprised *S. epidermidis* ($n=33$), *S. capitis* ($n=1$), *S. haemolyticus* ($n=1$), *S. simulans* ($n=1$) and *S. lugdunensis* ($n=1$). The minimum inhibitory concentrations (MICs, $\mu\text{g/mL}$) of all antimicrobials were determined using the Etest method (AB Biodisk, Solna, Sweden). Rifampicin and linezolid were tested in combination with each other and with clindamycin, fusidic acid, ciprofloxacin and trimethoprim–sulfamethoxazole (SXT), respectively. First, the MIC for each antimicrobial was determined according to the guidelines from the Swedish Reference Group for Antibiotics (SRGA; <http://www.srga.org>). For the combination (synergy) testing, two methods, fixed ratio and MIC/MIC ratio, were performed [15–17]. Briefly, in the fixed ratio method, an Etest strip of the first antimicrobial was placed on an agar plate, its exact location marked on the back of the plate, and incubated for 1 h at room temperature. Then, the Etest strip was removed and an Etest strip of the second antimicrobial was placed at the same location on the agar plate as the first strip. In the MIC/MIC ratio method, an Etest strip of the first antimicrobial was placed on an agar plate, with the location and the MIC value from the single testing marked on the back of the plate, and incubated for 1 h at room temperature. Then, the Etest strip was removed and an Etest strip of the second antimicrobial was superimposed so that the respective MIC values from the single testing were aligned. All tests were performed on IsoSensitest agar (Oxoid, Hampshire, England) and at 36°C aerobic atmosphere for 18–24 h.

In order to determine whether each specific combination of antimicrobials resulted in a synergistic, additive, indifferent or antagonistic effect, the fractional inhibitory concentration (FIC) index was calculated as previously described [15]. The following cut-off values and interpretative criteria in regards of the achieved effect were used; FIC index ≤ 0.5 indicated a synergistic effect, FIC index >0.5 and ≤ 1.0 an additive effect, FIC index >1.0 and ≤ 4.0 indifferent effect, and FIC index >4.0 an antagonistic effect [15]. Random isolates were repeatedly analysed in order to assess the reproducibility.

Results and discussion

The MIC values for all isolates and all antimicrobial agents in single use are shown in Table 1.

Altogether, 888 MIC determinations were performed using the fixed ratio method and the MIC/MIC ratio method. The results of the MIC/MIC ratio method were more reproducible and easier to interpret, especially when evaluating two antimicrobials with substantial differences in their MIC values. Accordingly, the results of the antimicrobial synergy testing, using Etest and the MIC/MIC ratio method, of all isolates and antimicrobial combinations are summarised in Table 2.

Overall, 16 (43%) of the isolates displayed a synergistic ($n=5$), additive ($n=14$) or antagonistic ($n=11$) effect when combining two antimicrobials (Table 2).

The combination of rifampicin and ciprofloxacin displayed no synergistic effect in vitro. Instead, there were two (5%)

Table 2 Antimicrobial synergy testing, using Etest, of coagulase-negative staphylococcal isolates ($n=37$) from prosthetic joint infections

Antimicrobial combination ^a	Number (%) of isolates			
	Synergism	Addition	Indifference	Antagonism
RI + LZ	0	0	36 (97%)	1 (3%)
RI + CI	0	0	35 (95%) ^b	2 (5%)
RI + FU	2 (5%)	0	35 (95%)	0
RI + CM	0	4 (11%) ^c	33 (89%)	0
RI + SXT	0	1 (3%)	36 (97%) ^d	0
LZ + CI	0	1 (3%)	35 (95%)	1 (3%)
LZ + FU	1 (3%)	6 (16%)	30 (81%) ^e	0
LZ + CM	2 (5%)	2 (5%)	30 (81%)	3 (8%)
LZ + SXT	0	0	33 (89%)	4 (11%)

^a RI, rifampicin; LZ, linezolid; CI, ciprofloxacin; FU, fusidic acid; CM, clindamycin; SXT, trimethoprim–sulfamethoxazole

^b Including one strain not possible to distinguish between indifferent and additive effect

^c Including two strains not possible to distinguish between additive and synergistic effect

^d Including two strains not possible to distinguish between indifferent and additive effect

^e Including one strain not possible to distinguish between indifferent and additive effect and one strain not possible to completely distinguish between additive and synergistic effect

isolates showing an antagonistic effect with an increase of the ciprofloxacin MIC from 6 µg/ml and 8 µg/ml, respectively, to >32 µg/ml. For rifampicin and fusidic acid, two isolates (5%) displayed a synergistic effect, with a decrease of the rifampicin MIC from >32 µg/ml to 8 µg/ml and 0.125 µg/ml, respectively, as well as of fusidic acid from 6 µg/ml and 12 µg/ml to 1.5 µg/ml and 0.064 µg/ml, respectively. For rifampicin and clindamycin, four isolates (11%) displayed an additive effect, with a decrease of the clindamycin MIC from >256 µg/ml ($n=3$) to 0.94 µg/ml ($n=2$) and 128 µg/ml, respectively, and one additional isolate displayed a decrease from 0.19 µg/ml to 0.064 µg/ml.

Linezolid comprises no known cross-resistance to other antimicrobials and is highly effective against Gram-positive bacteria. However, the treatment is expensive and long-term use may cause adverse effects [13, 18]. For the combination rifampicin and linezolid, no synergistic or additive effects were found in the present in vitro test, but in a previous study by Jacqueline et al. [19], using the time–kill curve method, an additive effect could be seen. This has also been indicated in clinical studies [13, 14]. Accordingly, this combination treatment may have a synergistic effect in vivo. Regarding linezolid and fusidic acid, almost 20% of the isolates displayed a positive effect (synergistic or additive). For linezolid and clindamycin, all three effects were found, i.e. two isolates (5%) displayed synergistic effect, two (5%) additive effects and three (8%) antagonistic effects. Clindamycin might be of clinical interest as the empirical treatment of PJIs, since it has a good effect on aerobic as well as anaerobic bacteria. Linezolid in combination with trimethoprim–sulfamethoxazole displayed the highest percentage of antagonistic effect (four isolates; 11%), with an increase of linezolid MIC by 2 to 3 whole MIC steps, while rifampicin and trimethoprim–sulfamethoxazole displayed no antagonistic effect and one isolate (3%) displayed an additive effect.

The reproducibility of the antimicrobial synergy testing using Etest was high (data not shown). Ideally, the Etest method for synergy testing of staphylococci should be further validated to a “gold standard,” such as checkerboard titration or any in vitro kinetic model for synergy testing. However, there have been studies comparing Etest, the time–kill curve method and/or checkerboard methods for organisms such as *Acinetobacter baumannii* [20], *Candida* species [21] and *Burkholderia cepacia* [15]. All of these studies concluded that Etest is simple to use, time-efficient, reproducible and has good agreement to other methods for synergy testing. However, additional investigations are needed. A limitation of this study was that only bacteria in the growth phase, and not in the stationary phase protected by biofilm, were examined. Accordingly, the results may not completely reflect the situation in vivo during a PJI,

but examine interesting antimicrobial combinations and their interactions in vitro.

In conclusion, Etest is an objective and easily performed in vitro method for the antimicrobial synergy testing of CoNS. However, the effects of different combinations of antimicrobials were strain-dependent and, accordingly, each isolate needs to be tested for the specific antimicrobial combination considered for treatment.

References

1. Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. *N Engl J Med* 351(16):1645–1654
2. Esposito S, Leone S (2008) Prosthetic joint infections: microbiology, diagnosis, management and prevention. *Int J Antimicrob Agents* 32(4):287–293
3. Zavasky DM, Sande MA (1998) Reconsideration of rifampin: a unique drug for a unique infection. *JAMA* 279(19):1575–1577
4. Collins DN, McKenzie JM (1991) Infections at the site of a hip implant. Successful and unsuccessful management. *Clin Orthop Relat Res* 269:9–15
5. Marculescu CE, Berbari EF, Hanssen AD, Steckelberg JM, Harmsen SW, Mandrekar JN, Osmon DR (2006) Outcome of prosthetic joint infections treated with debridement and retention of components. *Clin Infect Dis* 42(4):471–478
6. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE (1998) Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. *Foreign-Body Infection (FBI) Study Group. JAMA* 279(19):1537–1541
7. Trampuz A, Osmon DR, Hanssen AD, Steckelberg JM, Patel R (2003) Molecular and antibiofilm approaches to prosthetic joint infection. *Clin Orthop Relat Res* 414:69–88
8. Schwank S, Rajacic Z, Zimmerli W, Blaser J (1998) Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. *Antimicrob Agents Chemother* 42(4):895–898
9. Svensson E, Hanberger H, Nilsson LE (1997) Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing *Staphylococcus epidermidis* cells. *Antimicrob Agents Chemother* 41(1):107–111
10. Widmer AF, Frei R, Rajacic Z, Zimmerli W (1990) Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. *J Infect Dis* 162(1):96–102
11. Berdal JE, Skråmm I, Mowinckel P, Gulbrandsen P, Bjørnholt JV (2005) Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. *Clin Microbiol Infect* 11(10):843–845
12. Soriano A, García S, Bori G, Almela M, Gallart X, Macule F, Sierra J, Martínez JA, Suso S, Mensa J (2006) Treatment of acute post-surgical infection of joint arthroplasty. *Clin Microbiol Infect* 12(9):930–933
13. Soriano A, Gómez J, Gómez L, Azanza JR, Pérez R, Romero F, Pons M, Bella F, Velasco M, Mensa J (2007) Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. *Eur J Clin Microbiol Infect Dis* 26(5):353–356
14. Senneville E, Legout L, Valette M, Yazdanpanah Y, Beltrand E, Caillaux M, Migaud H, Mouton Y (2006) Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. *Clin Ther* 28(8):1155–1163
15. Manno G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M (2003) Use of the E test to assess synergy of antibiotic combinations against isolates of *Burkholderia cepacia*-complex from patients with cystic fibrosis. *Eur J Clin Microbiol Infect Dis* 22(1):28–34

16. Pankey GA, Ashcraft DS (2005) In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 49(7):2959–2964
17. Tsuji BT, Rybak MJ (2006) Etest synergy testing of clinical isolates of *Staphylococcus aureus* demonstrating heterogeneous resistance to vancomycin. *Diagn Microbiol Infect Dis* 54(1):73–77
18. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL (2004) Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. *Clin Infect Dis* 38(8):1058–1064
19. Jacqueline C, Caillon J, Le Mabecque V, Miegerville AF, Donnio PY, Bugnon D, Potel G (2003) In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant *Staphylococcus aureus* by time–kill curve methods. *J Antimicrob Chemother* 51(4):857–864
20. Bonapace CR, White RL, Friedrich LV, Bosso JA (2000) Evaluation of antibiotic synergy against *Acinetobacter baumannii*: a comparison with Etest, time–kill, and checkerboard methods. *Diagn Microbiol Infect Dis* 38(1):43–50
21. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME (2002) Comparison of Etest, checkerboard dilution and time–kill studies for the detection of synergy or antagonism between antifungal agents tested against *Candida* species. *J Antimicrob Chemother* 49(2):345–351